Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
My guess was that PIs worry over further placing, but what they forget is that only 4months ago - both private II's and existing II's participated in this exercise. REDX raised this capital to get porcupine trial in early 17 and are fully sorted for atleast next year. Who knows if REDX will be still here. SAR got swallowed last week and all their trails will be done in America. Good to see all buys coming in now. Some sense settling in. Confident we have found bottom here, at 60.
After numerous discovery and development of new drugs and one of the leader in bringing cancer cure medication, REDX is still less than IPO price. Ridiculous. SAR and other drugs, has been gobbled up by Americans recently for more than 140% than their current price. So I don't think REDX would be far off to be honest.
It is estimated that drug-resistance accounts for more than 0.5mln deaths globally each year and is expected to rapidly increase. A recent study suggests that number could rise to around 10mln by 2050, costing the global economy up to US$100trn according to projections from the World Bank. Coinciding with the UN meeting, the World Bank report said that the failure of antimicrobial drugs could cause low-income countries to lose more than 5% of their gross domestic product. The bank echoed earlier findings of the independent review on antibiotic resistance and predicts increases in healthcare costs around the world in the range of US$300bn to US$1trn per year by 2050.
Last week, the United Nations General Assembly pledged to tackle the concerning rise in drug-resistant bacteria. UN secretary general Ban Ki-moon said antibiotic resistance was a “fundamental threat” to global health. In a declaration signed last Wednesday, all 193 member states agreed to combat the proliferation of antibiotic resistance. Over- and improper use has meant a growing number of bacteria are becoming resistant to most available antibiotics. Even those marked as a “last resort” are becoming increasingly redundant in the fight against potentially fatal superbugs. The call for new antibiotics The discovery of new antibiotics has not kept pace with the increasing incidence of resistant bacteria. Global health bodies have stressed the importance of new antibiotics to replace those currently in circulation, some of which have been relied upon for decades. But a number of drug discovery companies are answering the global call for new antibiotics to tackle this crisis head-on. Better than the “last resort” Redx Pharmaceuticals on Tuesday announced its novel compounds (bacterial topoisomerase inhibitors) were highly effective against certain drug resistant strains of bacteria, and even out-performed currently available “last resort” drugs. This could have important implications for drug resistant infections such as E. coli and Pseudomonas, responsible for critical illnesses such as pneumonia and blood poisoning. “In 2014 there were over 750,000 cases of hospital-acquired pneumonia in the US and Europe. These infections are the primary cause of death in intensive care units, with mortality rates amongst ventilated patients reaching 50%,” said chief executive Neil Murray.
could do with some Dir buys here.
Already in online Share Mag - a small piece. I'm pretty sure we will get even more coverage in the coming issues and also in all other publishers this week. All to play for. REDX is a quick riser when it does. my target is 65p/70p tmrw and north of that in end of week.
Neil Murray, chief executive of Redx Pharma, said: “We have put an enormous research focus on fighting drug-resistant infection over the last three years and are excited by the breakthrough that our team has made. "The US Centre for Disease Control and Prevention estimated that antibiotic resistance is responsible for over two million infections. "In 2014 there were over 750,000 cases of hospital acquired pneumonia in the US and Europe. "These infections are the primary cause of death in intensive care units, with mortality rates amongst ventilated patients reaching 50 per cent. "Overall these infections cause an average increase in hospital stay of between 7-9 days per patient. "Unfortunately, many of these infections are becoming resistant to traditional antibiotics, meaning new drug regimens must be found. “Currently more than 50,000 people in Europe and the US alone die annually because of antibiotic resistance and the problem is getting worse year-on-year. "It is predicted that globally all drug-resistant infection will claim the lives of 10 million people annually by 2050 if we do not find a solution to this critical problem. "Developing a truly broad spectrum antibiotic that can treat infections caused by both Gram-negative, as well as Gram-positive bacteria, would therefore be a major breakthrough in the battle to combat life threatening diseases worldwide.” Redx will now be progressing these compounds with the objective of selecting an optimal lead compound to identify a development candidate that can be progressed into human clinical trials. DEMAND IS GOING TO BE HUGE. SERIOUSLY!!!
Redx, the drug development company, announces the discovery of a series of compounds that have the potential to create the first novel class of broad-spectrum antibiotics in 30 years. The research, conducted by Redx in its facilities at Alderley Park, Cheshire, found the compounds are highly effective against a range of drug resistant bacteria including Gram negative species such as E. coli and Pseudomonas which can be responsible for drug resistant forms of pneumonia, urinary tract infections, intra-abdominal infections and septicaemia. In the in vivo study, using a multi-drug resistant strain of bacteria, the lead compound achieved a significant decrease in bacterial infection levels which was equivalent to tigecycline, a current drug-of-last-resort used in treating antibiotic resistant bacteria. Bacteria are divided into two broad classes – Gram-positive and Gram-negative. The latter have a highly impermeable cell wall. They also possess the ability to expel drugs that do manage to cross the cell wall. This poses a huge challenge for healthcare providers as Gram-negative bacteria are increasingly becoming resistant to most available antibiotics. Neil Murray, chief executive of Redx Pharma, said: “We have put an enormous research focus on fighting drug-resistant infection over the last three years and are excited by the breakthrough that our team has made. "The US Centre for Disease Control and Prevention estimated that antibiotic resistance is responsible for over two million infections. "In 2014 there were over 750,000 cases of hospital acquired pneumonia in the US and Europe. "These infections are the primary cause of death in intensive care units, with mortality rates amongst ventilated patients reaching 50 per cent. "Overall these infections cause an average increase in hospital stay of between 7-9 days per patient. "Unfortunately, many of these infections are becoming resistant to traditional antibiotics, meaning new drug regimens must be found. “Currently more than 50,000 people in Europe and the US alone die annually because of antibiotic resistance and the problem is getting worse year-on-year. "It is predicted that globally all drug-resistant infection will claim the lives of 10 million people annually by 2050 if we do not find a solution to this critical problem. "Developing a truly broad spectrum antibiotic that can treat infections caused by both Gram-negative, as well as Gram-positive bacteria, would therefore be a major breakthrough in the battle to combat life threatening diseases worldwide.” Redx will now be progressing these compounds with the objective of selecting an optimal lead compound to identify a development candidate that can be progressed into human clinical trials. The breakthrough comes days after the 193 member states of the United Nations signed a symbolic declaration to tackle the “fundamental threatR
great news. THis is get us over the 70p mark we tested only few weeks back. great consolidation and we will find new base from now on. The retreat is complete and now moving on to 70/80 soon, my guess is towards 100p.
issued by brokers since June/July 2016. And has be reiterated.
no. can you please summarise?
More upbeat news on car market published in today's papers. Biggest car sales in August 2016 since records began. Jolly good. Can only mean one thing for us - 70p.
is come and gone unfortunately.
Vertu’s virtues underrated Canny management and copper-bottomed balance sheet are strengths for car dealer James Crux Share price weakness at ambitious automotive retailer Vertu Motors (VTU:AIM) represents an attractive entry point for investors. While Brexit could impact spending on big-ticket purchases including cars, Vertu has growth levers to pull and a reassuringly strong balance sheet under the bonnet. Since floating in 2006 with a stated ‘buy-and-build’ strategy, Vertu has grown into the UK’s fifth largest automotive retailer, trading under brands including Bristol Street Motors, Vertu and Macklin Motors. Shares have drifted down from 78p in January to 50.25p, reflecting worries about a new car market cooling and the impact of an EU exit on the industry. Yet Vertu’s pre-close update (1 Sep) highlighted robust half-year trading and astute CEO Robert Forrester still expects to deliver record full-year sales and profit. SMMT data since April shows the trend in UK private vehicle sales slowing following a period of sustained growth to record levels and Vertu’s September new car orders have indeed cooled. However high-quality, repeatable aftersales and used car sales, speaking for the bulk of profitability, continue to grow. ‘The result of the referendum to leave the European Union has, to date, not impacted consumer confidence as adversely as some were initially predicting and the group has not experienced any significant change in consumer behaviour,’ says Vertu. Record low interest rates and record employment in the UK provide a healthy backdrop for the motor retail sector, although the weak pound creates uncertainties around manufacturers’ strategies on pricing. It is worth pointing out that the UK represents the second biggest market for new vehicles in the current EU and thousands of continental European jobs are reliant on a continuation of this trade with the UK, so manufacturers will be keen to support UK retailers through the uncertainty. Vertu is well-placed to profit from prevailing conditions through its established network of volume and premium car dealerships and can turbo-charge earnings through M&A, having proven its ability to acquire and turn round underperforming dealerships. Vertu has a strong, asset-backed balance sheet and the majority of the £35 million raised in a March placing has been deployed in earnings-enhancing acquisitions. Liberum has a ‘buy’ rating and 100p price target for Vertu. For the year to February 2017, the broker forecasts growth in adjusted pre-tax profits to £31.4 million (2016: £27.4 million) for 6.2p of earnings and a maintained 1.3p dividend. On these metrics, Vertu looks oversold on a grudging PE of 8 with a 2.6% dividend yield. Shares says BUY : "Vertu Motors is significantly oversold at 50.25p."
:) 80p
Redx Pharma Plc (LON:REDX) has a ‘potent combination’ of assets, according to the drugs analyst at City broker Cantor Fitzgerald. Providing the backbone to Dr Brian White’s 105p a share valuation is a potentially “best in class” Porcupine inhibitor, which should undergo first-in-human studies early next year. Porcupine inhibitors are a new method of fighting the killer disease. They work by targeting cancer stems cells that can often lie dormant after traditional treatment and are associated with a recurrence of the illness. Kill the stem cells and you have a chance of eradicating the disease completely. Novartis currently is the only drug major with a Porcupine inhibitor in the clinic and Redx is using the Swiss giant’s compound as its benchmark “with a view to coming up with something better”. Cantor’s White said these Porcupine drugs could be used in combination checkpoint inhibitors to increase the potency of the cancer treatment. He added: “Cancer R&D has heavily featured the pharmaceutical industry’s continued quest to find appropriate combinations with checkpoint inhibitors and which has resulted in several high profile and valuable transactions.” The 105p net present value stands at a significant premium to the current share price of 35.6p. Also in the Redx portfolio is a next-generation of Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of leukaemia. Redx’s BTK will be one of the second-generation of compounds with fewer side-effects than the market leader Imbruvica (Ibrutinib). More importantly, the company’s drug is targeted at overcoming resistance that patients have developed to ibrutinib. Redx hopes to have selected a candidate by the end of this year ready to go into the clinic in early 2018. That’s far from the end of the story for the oncology pipeline, which includes a smoothened inhibitor for basal cell carcinoma (a form of skin cancer). It is also developing a compound that inhibits IDO, a pathway active in many cancers and it is working on a number of targets in the emerging area of immuno-oncology. In anti-infectives, Redx has teamed up with the Liverpool and Broadgreen University Hospital NHS Trust to develop drugs to tackle gram-positive bacteria such as MRSA. "Critically, these are novel drug scaffolds, so they are potentially the first new class of antibiotics in a generation,” said chief executive Neil Murray in a recent interview. “One of the main reasons that we are facing such a critical shortage of antibiotics that still work is because our industry has been unable to create new classes of drugs.” Not just that, they are designed in a way to make it very difficult for the bacteria to evolve resistance. Redx also has a programme developing drugs to combat Gram-negative strains. It is already having some early success with gonorrhoea w
£1 is good.
I guarantee we will see delayed buys today.
one thing is for sure, when redx rises it rises fast. yesterdays news was transformational for the company.